Palliser Capital Challenges Recordati’s Board Over €51.29 Tender Offer, Calls for €60 per Share
Event summary
- Palliser Capital publicly issued a letter to Recordati’s Board on September 1, 2026, urging withdrawal of support for Respighi BidCo’s €51.29-per-share tender offer.
- Palliser argues the offer undervalues Recordati and unfairly prejudices minority shareholders, calling for a price increase to no less than €60 per share.
- The letter highlights flaws in the valuation process, governance conflicts, and coercion of minority shareholders.
- Six non-independent directors pushed the offer through despite unanimous opposition from all four independent directors.
- Palliser claims the offer lacks independent endorsement and is structured to pressure shareholders into accepting an inadequate deal.
The big picture
Palliser Capital’s challenge to Recordati’s Board highlights a growing trend of activist investing targeting undervalued tender offers in the pharmaceutical sector. The dispute underscores the tension between independent directors and those with conflicts of interest, raising questions about the fairness of the process and the protection of minority shareholders. The outcome could set a precedent for similar situations where consortium-led offers face scrutiny over valuation and governance practices.
What we're watching
- Governance Dynamics
- Whether Recordati’s Board will address the governance conflicts and reconsider its support for the tender offer.
- Valuation Dispute
- How the valuation gap between Palliser’s proposed €60 per share and the current €51.29 offer will be resolved.
- Shareholder Pressure
- The pace at which minority shareholders may mobilize in response to Palliser’s allegations of coercion.
Related topics